Thursday 19 November 2026

GamersDXB: Gateway to Business, Tech, and Startup Insights

Potential New Treatment Option for Relapsed Multiple Myeloma

Ciltacabtagene autoleucel (cilta-cel; Carvykti) may offer “another path” for patients with multiple myeloma apart from standard options including chemotherapy and stem cell transplantation, according……

Potential New Treatment Option for Relapsed Multiple Myeloma

Ciltacabtagene autoleucel (cilta-cel; Carvykti) is showing promise as a potential treatment option for patients with multiple myeloma, offering a new path apart from traditional methods such as chemotherapy and stem cell transplantation. Ishmael Applewhite, BSN, RN-BC, OCN, a registered nurse at the University of Rochester Medical Center, discussed the results of the phase 3 CARTITUDE-4 trial (NCT04181827) at the 2024 Oncology Nursing Society (ONS) Congress.

While there is currently no cure for multiple myeloma, cilta-cel is offering patients extended survival time. Applewhite recommends considering the use of this agent in later stages of treatment for maximum benefit.

The findings from the CARTITUDE-4 trial revealed an impressive overall response rate of 99.4% in patients who received cilta-cel, with 86.4% achieving a complete response or better. The 12-month progression-free survival rate was 90%, and the 12-month overall survival rate was 92% among the treated population.

In Applewhite’s view, cilta-cel presents an opportunity to extend the lives of patients with multiple myeloma, providing hope for those who have exhausted other treatment options. Although cost is a consideration, integrating cilta-cel into the treatment pathway could offer patients more time while researchers continue to explore new therapies.

The results of the CARTITUDE-4 trial suggest that cilta-cel has the potential to become a new standard-of-care for patients with multiple myeloma, offering a ray of hope in the fight against this challenging disease.

ShareXLinkedInWhatsAppEmail